Journal of Neurology Neurosurgery & Psychiatry · 2005 · 73 citations · 9 references
MedicinePharmacotherapyClinical PharmacologyHypersensitivityPain ManagementLambert-eaton Myasthenic SyndromeMyasthenia GravisLong-term Medication UseMean ReductionMyasthenia Gravis PharmacotherapyPrednisolone UseReduction Ratio
Efficacy and safety of long term use of FK506 (2-4.5 mg/day) for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG). At the end of the study, eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be reduced in seven patients (58%), with a mean reduction ratio of 37%. Long term use of FK506 for MG can be more effective than short term administration, with no serious side effects.
9
Toru Kino, Hiroshi Hatanaka, MICHISANE HASHIMOTO et al. · The Journal of Antibiotics · 1987 · 1.2K citations · Full text
Medicine, Biochemistry, Pharmacology +10
U. A. Besinger, Klaus V. Toyka, Martina Hömberg et al. · Neurology · 1983 · 275 citations
Life Sciences, Immunology, Neurology +17